.png)
Mid-size Biopharmaceutical
Market Access, HEOR, Medical Affairs
Phase III
Oncology
Subscribe to our newsletter to receive the latest case studies.
Mid-size Biopharmaceutical
Market Access, HEOR, Medical Affairs
Phase III
Oncology
A mid-size biopharmaceutical company was 18 months from launch of a therapy for a rare oncologic disease with no prior approved treatments.
Success would depend on more than approval. The team needed a clear value story, payer-relevant evidence, regulatory-aligned messaging, and strong positioning in clinical guidelines.
The client engaged Alkemi to develop and execute a coordinated evidence and communication strategy to support access and adoption at launch.
1. Developed an early value story mapping disease burden, unmet need, product value drivers, and evidence gaps.
2. Designed evidence generation initiatives, including RWE strategy and patient burden research to strengthen the value case.
3. Created a PRO-focused communications strategy to articulate the importance of the primary endpoint to regulators and investors.
4. Developed an AMCP dossier and payer-facing tools to support launch discussions.
5. Built guideline positioning communications to advocate for inclusion in clinical practice guidelines.
Align evidence, messaging, and payer strategy well before approval.
"Alkemi helped us build a cohesive evidence and communication strategy that strengthened our value story and positioned us for a successful launch.” - Senior Director, Market Access
A favorable NCCN guideline update advocating use of the therapy was issued within 10 days of approval.
The therapy secured coverage across major commercial and public U.S. payers.
Integrated planning across evidence and access enabled a coordinated, confident market entry.